PRT-060318

PRT-060318 (PRT318) s a potent, selective and orally active tyrosine kinase Syk inhibitor with an IC50 of 3 nM. PRT-060318 suppresses chronic lymphocytic leukemia (CLL) B cell activation and migration, and induces apoptosis. PRT-060318 prevents Heparin (HY-17567) -induced thrombocytopenia and thrombosis in a transgenic mouse model. PRT-060318 dihydrochloride can be used for CLL and thrombus research[1][2].

Product Specifications

CAS Number

[1194961-19-7]

Product Name Alternative

PRT318

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Apoptosis; Syk

Type

Reference compound

Related Pathways

Apoptosis; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/PRT-060318.html

Purity

99.59

Solubility

DMSO : 10 mg/mL (ultrasonic; warming; adjust pH to 3 with 1 M HCL; heat to 60°C) |H2O : 25 mg/mL (ultrasonic)

Smiles

O=C(C1=CN=C(N[C@H]2[C@@H](N)CCCC2)N=C1NC3=CC=CC(C)=C3)N

Molecular Formula

C18H24N6O

Molecular Weight

340.42

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Reilly MP, et al. PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model. Blood. 2011 Feb 17;117 (7) :2241-6.|[2]Hoellenriegel J, et al. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia. 2012 Jul;26 (7) :1576-83.